Posts tagged "medicine"
My Interview with Rick Doblin, Psychedelic Pioneer & Founder of MAPS

My Interview with Rick Doblin, Psychedelic Pioneer & Founder of MAPS

I recently had the good fortune of meeting my psychedelic hero, Rick Doblin, the founder and president of the Multidisciplinary Association of Psychedelic Studies. What’s more, he graciously agreed to an on-camera interview! I asked him about the origins of MAPS, the Russian ban of methadone in Crimean addiction clinics, New Zealand’s new regulatory framework for legal highs, MAPS’ recent partnership with the military to research MDMA as a treatment for PTSD, and much more. My favorite part is when Rick tells the story of taking LSD on his twenty-first birthday. He heard a siren and became convinced that the Russians were bombing Tampa,...
MAPS Completes First New Therapeutic LSD Study in 40 Years

MAPS Completes First New Therapeutic LSD Study in 40 Years

Update 5 March 2014: The study has been published, and the final copy is available here. Rick Doblin, the founder and president of MAPS, said this in a recent “Ask Me Anything” interview on Reddit: We’ve just completed the world’s first study of the therapeutic use of LSD in over 40 years, in Switzerland to treat anxiety associated with end-of-life issues. Eleven of the 12 subjects had never done LSD before and there were no serious adverse events, even in people facing death. This recently completed Swiss study is truly momentous — it’s the first “double-blind, placebo-controlled investigation of LSD-assisted psychotherapy since...
"Ask Me Anything" Reddit Interview with Rick Doblin & MAPS

“Ask Me Anything” Reddit Interview with Rick Doblin & MAPS

Yesterday, Rick Doblin and ten other MAPS staff members engaged in an online “Ask Me Anything” session on Reddit. The turnout was phenomenal. Questions ran the gamut from personal (“Have you ever tried psychedelics?”) to political (“Will the legalization of psychedelics will come next after marijuana?”) and much more. Several posters asked about minimizing the risk of MDMA toxicity, while others were curious about treatments for cluster headaches, depression, autism, and other conditions. A couple people even asked if MAPS accepts Bitcoin (as of yesterday, they do). As you might expect, the answers from MAPS staff were incredibly informative and...
Help Heal Trauma Survivors by Supporting MDMA Research

Help Heal Trauma Survivors by Supporting MDMA Research

MAPS, the Multidisciplinary Association for Psychedelic Studies, has been an instrumental force in psychedelic research and advocacy since its formation in 1986. In my opinion, this non-profit organization has done more to establish psychedelics as legitimate medicines than anyone else in the world. Their biggest project is proving the safety and effectiveness of MDMA-assisted therapy as a treatment for post-traumatic stress disorder (PTSD). They have performed a number of studies around the world indicating its effectiveness — even with the one-third of PTSD patients who do not respond adequately to other treatments. As you can imagine, MAPS does not have...
FDA Approves Lorcaserin, Diet Drug with Psychedelic Effects at High Doses

FDA Approves Lorcaserin, Diet Drug with Psychedelic Effects at High Doses

This is a landmark step towards sensible US drug policy. Since the Nixon Administration passed the Controlled Substance Act passed in 1970, nearly all psychedelic-style drugs have been automatically classified as Schedule I, which means absolute prohibition with no recognized medical potential.  (LSA presents an exception as a Schedule III drug, and the case may be made for the “psychedelic” nature of dextromethorphan and ketamine.) Lorcaserin, a weight loss drug with euphoric, hallucinogenic, and dissociative effects at high doses, has been classified as a Schedule IV medicine. This marks the first time that the DEA has acknowledged the medical benefits...
Ketamine shows promise in treating "Fear of Harm"

Ketamine shows promise in treating “Fear of Harm”

There has been a huge resurgence of research on psychedelic and dissociative drugs recently. This is very promising because for 40 years, the study of these very promising medical compounds was shelved in the name of prohibition. Finally, after decades of hiatus, we are able to shed light on some of these compounds in controlled clinical settings. The studies may be small and few in number right now, but their positive results should help open the door to larger and ever more diverse studies. If early studies are any indication, the medical potential of psychedelics is absolutely vast. What a...